LDS/Medical Tests/Procainamide, Urine, or Serum

Procainamide, Urine, or Serum

Procainamide is used in the treatment of atrial and ventricular arrhythmias. The actions of this drug are similar to quinidine and can be used as a substitute in some instances. Procainamide is metabolized by the liver to N-acetylprocainamide (NAPA), the active metabolite, by NAPA-transferase. The rate of this metabolism varies between individuals as the activity of the transferase is predetermined by each individual’s genetic makeup. Fast metabolizers have a NAPA level equal to or greater than the procainamide concentration at three hours post dosage. Procainamide works by increasing the refractory period of the atria, the bundle of His-Purkinje system, and the ventricles of the heart. The method of administration of procainamide will determine the time in which levels will peak in the plasma. Dosage should be monitored by serial samples collected using the same time interval between sampling. For injection or IV administration, plasma levels will peak between 15 and 60 minutes; for oral administration the levels will peak in 90 to 120 minutes. The half-life is between 2 and 6 hours. Moderate to severe renal disease generally results in increased half-life characteristics.

Since procainamide and its main metabolite NAPA both have antiarrhythmic activity, therapeutic monitoring usually involves measurement of both. Effective therapeutic concentrations of procainamide range from 4 to 10 µg/mL, with toxicity at levels greater than 12 µg/mL. When measuring serum levels of both procainamide and NAPA it is generally thought best to keep the total concentration less than 30 µg/mL, as toxic effects begin to appear when total levels are greater than 35 µg/mL. It has been reported that long-term use leads to the development of antinuclear antibodies (ANA) in 50% of patients and 20%-30% of patients may develop a lupus-like syndrome. A benefit-versus-risk assessment should be performed for continued therapy if an ANA titer develops.

  • Monitor therapy
  • Assess compliance
  • Evaluate for toxicity

Increased in:

  • Toxicity

Decreased in:

  • Under dosage
Category mcg/mL µmol/L
Therapeutic concentration* 10–20 36.1–72.2
Toxic concentration >40 >144

*NAPA should be analyzed in conjunction with procainamide concentrations.

Enzyme immunoassay (EIA), Fluorescent polarization immunoassay (FPIA), High performance liquid chromatography/mass spectrometry (HPLC/MS), Gas chromatography/mass Spectrophotometry (GC/MS).

Serum (Red top) preferred, Plasma EDTA (Lavender), Heparin (Green), urine collected in a sterile container. 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Antinuclear Antibody, Serum creatinine, Serum BUN, eGFR.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Bishop ML, Duben-Engelkirk JL, Fody EP. Clinical Chemistry Principles, Procedures, Correlations. Philadelphia. Lippincott (1996).
  • Lehmann CA. Saunders Manual of Clinical Laboratory Science. Philadelphia. W.B. Saunders Company (1998).